BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28061436)

  • 1. Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
    Hontecillas-Prieto L; Garcia-Dominguez DJ; Vaca DP; Garcia-Mejias R; Marcilla D; Ramirez-Villar GL; Saez C; de Álava E
    Oncotarget; 2017 Feb; 8(7):11173-11186. PubMed ID: 28061436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of TCF3 as potential master regulator in blastemal Wilms tumors.
    Kehl T; Schneider L; Kattler K; Stöckel D; Wegert J; Gerstner N; Ludwig N; Distler U; Tenzer S; Gessler M; Walter J; Keller A; Graf N; Meese E; Lenhof HP
    Int J Cancer; 2019 Mar; 144(6):1432-1443. PubMed ID: 30155889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of the multidrug resistance-related protein MRP1 in the histological compartments of nephroblastomas.
    Efferth T; Thelen P; Schulten HG; Bode ME; Granzen B; Beniers AJ; Mertens R; Ringert RH; Gefeller O; Jakse G; Fuzesi L
    Int J Oncol; 2001 Aug; 19(2):367-71. PubMed ID: 11445853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunolocalization of ABC drug transporters in human placenta from normal and gestational diabetic pregnancies.
    Kozłowska-Rup D; Czekaj P; Plewka D; Sikora J
    Ginekol Pol; 2014 Jun; 85(6):410-9. PubMed ID: 25029804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy.
    Citti A; Boldrini R; Inserra A; Alisi A; Pessolano R; Mastronuzzi A; Zin A; De Sio L; Rosolen A; Locatelli F; Fruci D
    Int J Oncol; 2012 Jul; 41(1):117-24. PubMed ID: 22504834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
    Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined cytogenetic and array-based comparative genomic hybridization analyses of Wilms tumors: amplification and overexpression of the multidrug resistance associated protein 1 gene (MRP1) in a metachronous tumor.
    Goldstein M; Rennert H; Bar-Shira A; Burstein Y; Yaron Y; Orr-Urtreger A
    Cancer Genet Cytogenet; 2003 Mar; 141(2):120-7. PubMed ID: 12606129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients.
    Hontecillas-Prieto L; García-Domínguez DJ; García-Mejías R; Ramírez-Villar GL; Sáez C; de Álava E
    Oncotarget; 2017 Dec; 8(70):115290-115303. PubMed ID: 29383160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk blastemal Wilms tumor can be modeled by 3D spheroid cultures in vitro.
    Wegert J; Zauter L; Appenzeller S; Otto C; Bausenwein S; Vokuhl C; Ernestus K; Furtwängler R; Graf N; Gessler M
    Oncogene; 2020 Jan; 39(4):849-861. PubMed ID: 31562394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
    Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
    Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
    Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
    Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade.
    Komdeur R; Plaat BE; van der Graaf WT; Hoekstra HJ; Hollema H; van den Berg E; Zwart N; Scheper RJ; Molenaar WM
    Eur J Cancer; 2003 May; 39(7):909-16. PubMed ID: 12706359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group.
    Mitchell C; Pritchard-Jones K; Shannon R; Hutton C; Stevens S; Machin D; Imeson J; Kelsey A; Vujanic GM; Gornall P; Walker J; Taylor R; Sartori P; Hale J; Levitt G; Messahel B; Middleton H; Grundy R; Pritchard J;
    Eur J Cancer; 2006 Oct; 42(15):2554-62. PubMed ID: 16904312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
    Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
    Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
    J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of the lung resistance-related protein/major vault protein in the histological compartments of nephroblastomas.
    Efferth T; Bode ME; Schulten HG; Thelen P; Granzen B; Beniers AJ; Mertens R; Gefeller O; Ringert RH; Jakse G; Fuzesi L
    Int J Oncol; 2001 Jul; 19(1):163-8. PubMed ID: 11408938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
    Sehic D; Karlsson J; Sandstedt B; Gisselsson D
    Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.